Characteristics of studies that evaluated inherited thrombophilia in women undergoing assisted reproductive technology
| Study . | Design . | Thrombophilia . | Participants . |
|---|---|---|---|
| Azem (2004)17 | Case-control | FVL, prothrombin mutation, MTHFR, protein C and S, AT | Cases: ≥ 4 IVF failures (n = 45); controls: healthy women, (n = 44); live birth after the first IVF attempt (n = 15) |
| Bellver (2008)18 | Case-control | FVL, prothrombin mutation, MTHFR, protein C and S, AT, APCR | Cases: repeated unexplained IVF failure (n = 26); controls: healthy women (n = 32) |
| Grandone (2001)8 | Case-control | FVL, prothrombin mutation, MTHFR, protein C and S, AT | Cases: at least 3 IVF failures (n = 18); controls: healthy women (n = 216) |
| Martinelli (2003)9 | Case-control | FVL, protrombin mutation, MTHFR | Cases: ≥ 1 IVF failures (n = 162);* controls: healthy women (n = 234) |
| Martinuzzo (2005)19 | Case-control | FVL, prothrombin mutation | Cases: ≥ 2 IVF failures (n = 48); controls: healthy women (n = 80) |
| Qublam (2006)20 | Case-control | FVL, prothrombin mutation, MTHFR, proteins C and S, AT | Cases: ≥ 3 IVF failures (n = 90); controls: live birth after the first IVF attempt (n = 90); healthy women (n = 100) |
| Rudick (2009)21 | Prospective cohort | FVL | Women undergoing IVF (n = 182) |
| Simur (2009)22 | Case control | FVL, prothrombin mutation, MTHFR | Cases: ≥ 3 IVF failures (n = 51); controls: healthy women (n = 50) |
| Tormene (2011)23 | Prospective cohort | FVL, prothrombin mutation, MTHFR | Women undergoing IVF (n = 201) |
| Vaquero (2006)24 | Case-control | FVL, prothrombin mutation, MTHFR | Cases: ≥ IVF failures (n = 59); controls: healthy women (n = 20) |
| Study . | Design . | Thrombophilia . | Participants . |
|---|---|---|---|
| Azem (2004)17 | Case-control | FVL, prothrombin mutation, MTHFR, protein C and S, AT | Cases: ≥ 4 IVF failures (n = 45); controls: healthy women, (n = 44); live birth after the first IVF attempt (n = 15) |
| Bellver (2008)18 | Case-control | FVL, prothrombin mutation, MTHFR, protein C and S, AT, APCR | Cases: repeated unexplained IVF failure (n = 26); controls: healthy women (n = 32) |
| Grandone (2001)8 | Case-control | FVL, prothrombin mutation, MTHFR, protein C and S, AT | Cases: at least 3 IVF failures (n = 18); controls: healthy women (n = 216) |
| Martinelli (2003)9 | Case-control | FVL, protrombin mutation, MTHFR | Cases: ≥ 1 IVF failures (n = 162);* controls: healthy women (n = 234) |
| Martinuzzo (2005)19 | Case-control | FVL, prothrombin mutation | Cases: ≥ 2 IVF failures (n = 48); controls: healthy women (n = 80) |
| Qublam (2006)20 | Case-control | FVL, prothrombin mutation, MTHFR, proteins C and S, AT | Cases: ≥ 3 IVF failures (n = 90); controls: live birth after the first IVF attempt (n = 90); healthy women (n = 100) |
| Rudick (2009)21 | Prospective cohort | FVL | Women undergoing IVF (n = 182) |
| Simur (2009)22 | Case control | FVL, prothrombin mutation, MTHFR | Cases: ≥ 3 IVF failures (n = 51); controls: healthy women (n = 50) |
| Tormene (2011)23 | Prospective cohort | FVL, prothrombin mutation, MTHFR | Women undergoing IVF (n = 201) |
| Vaquero (2006)24 | Case-control | FVL, prothrombin mutation, MTHFR | Cases: ≥ IVF failures (n = 59); controls: healthy women (n = 20) |
FVL indicates factor V Leiden; AT, anti-thrombin; and APCR indicates activated protein C resistance.
Cases followed prospectively to assess pregnancy outcomes.